Spotlight On... Patheon pairs with Grünenthal on abuse-deterrent R&D; Covance sells a U.K. lab; and more...

Patheon signed a deal with German drugmaker Grünenthal to help develop abuse-deterrent formulations of controlled substances. Under the agreement, Patheon will be the preferred development partner in Grünenthal's efforts to use its proprietary technology to craft opioids, depressants and stimulants with reduced abuse potential. Neither side disclosed financial information. More

> Covance sold a U.K. preclinical research site to investment group Shott Trinova. News

> WuXi PharmaTech launched an app called LabNetwork, which allows chemists to search a database of research chemicals and order them. Item

> Boston's inviCRO and Molecular NeuroImaging are merging operations, creating a unified company that offers imaging services to drugmakers. Release

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity.

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.